Functional analysis of the interleukin-1-receptor-associated kinase (IRAK-1) in interleukin-1β-stimulated nuclear factor κB (NF-κB) pathway activation:: IRAK-1 associates with the NF-κB essential modulator (NEMO) upon receptor stimulation

被引:34
作者
Cooke, EL
Uings, IJ
Xia, CLL
Woo, P
Ray, KP
机构
[1] GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, Dept Cell Biol, Stevenage SG1 2NY, Herts, England
[2] UCL, WIndeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England
关键词
I kappa B kinase (IKK); interleukin-1 signal transduction; tumour necrosis factor (TNF); ubiquitination;
D O I
10.1042/0264-6021:3590403
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interleukin-1 (IL-1)-receptor-associated kinase (IRAK-1) is essential for IL-1-stimulated nuclear factor kappaB (NF-kappaB ) activation. To study the role of IRAK-1 in IL-1 beta signalling, we have generated a set of IRAK-1 variants that express distinct domains of IRAK-1 either alone or in combination and have examined their effects on an NF-kappaB -responsive reporter in HeLa cells. Unlike full-length IRAK-1, the deletion mutants were unable to activate NF-kappaB in the absence of cytokine stimulation. However, an IRAK-1 variant lacking only the N-terminal domain retained the ability of the full-length protein to potentiate both IL-1 beta and tumour necrosis factor a (TNF alpha)-induced NF-kappaB activation. In contrast, expression of the N-terminus or the C-terminus of IRAK-1, or a fusion protein incorporating both domains, inhibited both IL-1 beta- and TNF alpha -induced effects. Expression of an IRAK-1 variant lacking only the C-terminal domain preferentially inhibited IL-1 beta versus TNF alpha -induced NF-kappaB activation. These data suggest that the C-terminal domain may link IRAK-1 to downstream signalling components common to both the IL-1 and TNF pathways. Furthermore, we have demonstrated that endogenous IRAK-1 becomes phosphorylated upon IL-1 beta treatment and can be detected along with NF-kappaB essential modulator (NEMO) and I kappaB kinase (IKK beta) in high-molecular-mass complexes of 600-800 kDa. Moreover, IRAK-1 could be detected in NEMO immunoprecipitates from IL-1 beta -stimulated cells. We conclude that IRAK-1 mediates IL-1 beta signal transduction through a ligand-dependent association of IRAK-1 with the IKK complex.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 43 条
[11]   A cytokine-responsive I kappa B kinase that activates the transcription factor NF-kappa B [J].
DiDonato, JA ;
Hayakawa, M ;
Rothwarf, DM ;
Zandi, E ;
Karin, M .
NATURE, 1997, 388 (6642) :548-554
[12]   Biologic basis for interleukin-1 in disease [J].
Dinarello, CA .
BLOOD, 1996, 87 (06) :2095-2147
[13]   THE I-KAPPA-B PROTEINS - MEMBERS OF A MULTIFUNCTIONAL FAMILY [J].
GILMORE, TD ;
MORIN, PJ .
TRENDS IN GENETICS, 1993, 9 (12) :427-433
[14]   MOLECULAR-CLONING AND CHARACTERIZATION OF A 2ND SUBUNIT OF THE INTERLEUKIN-1 RECEPTOR COMPLEX [J].
GREENFEDER, SA ;
NUNES, P ;
KWEE, L ;
LABOW, M ;
CHIZZONITE, PA ;
JU, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (23) :13757-13765
[15]   PROTEIN KINASES .6. THE EUKARYOTIC PROTEIN-KINASE SUPERFAMILY - KINASE (CATALYTIC) DOMAIN-STRUCTURE AND CLASSIFICATION [J].
HANKS, SK ;
HUNTER, T .
FASEB JOURNAL, 1995, 9 (08) :576-596
[16]   TNF-Dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex [J].
Hsu, HL ;
Huang, JN ;
Shu, HB ;
Baichwal, V ;
Goeddel, DV .
IMMUNITY, 1996, 4 (04) :387-396
[17]   TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways [J].
Hsu, HL ;
Shu, HB ;
Pan, MG ;
Goeddel, DV .
CELL, 1996, 84 (02) :299-308
[18]   Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein [J].
Huang, JN ;
Gao, X ;
Li, S ;
Cao, ZD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) :12829-12832
[19]   Prevention of constitutive TNF receptor 1 signaling by silencer of death domains [J].
Jiang, YP ;
Woronicz, JD ;
Liu, W ;
Goeddel, DV .
SCIENCE, 1999, 283 (5401) :543-546
[20]  
Knop J, 1998, EUR J IMMUNOL, V28, P3100, DOI 10.1002/(SICI)1521-4141(199810)28:10<3100::AID-IMMU3100>3.0.CO